Search clinical trials for: TKI 258

Total 635 results

Sichuan Provincial People's Hospital

Unknown

Hypofractionated Brain Radiation In EGFR Mutated Adenocarcinoma Cranial Disease (Hybrid) (Hybrid)

Stage IV EGFR Mutated NSCL With Brain Metastases

China
Shanghai Pulmonary Hospital, Shanghai, China

Unknown

EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism

Non-Small-Cell Lung Cancer
Georgetown University
Novartis

Terminated

Maintenance Dovitinib for Colorectal and Pancreas Cancer

Colorectal Cancer | Pancreas Cancer

United States
Shanghai University of Traditional Chinese Medicine
Shanghai Chest Hospital

Unknown

Efficacy Study of Chinese Medicine Plus EGFR-TKI Versus EGFR-TKI in Advanced Pulmonary Adenocarcinoma

Cancer
Novartis Pharmaceuticals

Terminated

Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer

Metastatic Breast Cancer

South Africa, France, Italy, Taiwan, Hungary, Belgium, Spain, Austria, Netherlands, Poland, Russian Federation, United States, Argentina, Brazil, Peru
AstraZeneca

Completed

Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient

Cancer | Advanced Solid Malignancies

Japan
Yuankai Shi

Unknown

Chidamide With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer
Zhejiang Cancer Hospital

Unknown

Acquired Resistant Mechanism of the First-generation EGFR TKIs

Non-small Cell Lung Cancer | Aquired Resistance | EGFR TKIs

China
First People's Hospital of Hangzhou

Unknown

A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy

Lung Adenocarcinoma | EGFR Positive Non-small Cell Lung Cancer
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib

Gastrointestinal Stromal Tumors

France, Italy, Spain, Germany, Finland
PD Dr. Martin Glas

Unknown

Dovitinib (TKI258) in the Treatment of Patients With Relapsed Glioblastoma (TKI258)

First or Second Recurrence of Glioblastoma

Germany
Sun Yat-sen University

Unknown

Detection Cell Free DNA in Lung Cancer Patients

Non-small Cell Lung Cancer

China
Hangzhou Cancer Hospital

Unknown

RT Plus EGFR-TKI for Wild-type NSCLC

Non-small Cell Lung Cancer | Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)

China
Bristol-Myers Squibb

Completed

Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib

Chronic Myeloid Leukemia (CML)
German Cancer Research Center

Completed

Reduction of Cancer Related Fatigue in Patients During TKI Therapy (RECAP)

All Tumor Entities Treated With TKI Therapy

Germany
Sun Yat-sen University

Unknown

A Retrospective Study About Treatment Strategy After First/Second Line EGFR-TKI Failure

Non-Small Cell Lung Cancer

China
GenoSaber
Sun Yat-sen University; Shanghai Chest Hospital; Shanghai Pulmonary Hospital,...

Unknown

Human EGFR Mutations Quantitative Detection Kit (Real-time Fluorescent PCR Method)

Non Small Cell Lung Cancer | EGFR-TKI Resistant Mutation | EGFR-TKI Sensitizing Mutation
GenoSaber

Unknown

EGFR Mutation Detection From Advanced NSCLC Patient Tissue and Plasma in EGFR-TKI Treatment

Non-small Cell Lung Cancer
Tianjin Medical University Cancer Institute and...

Unknown

Erlotinib Concurrent With Radiation Therapy in Non-small-cell Lung Cancer

Carcinoma, Non-Small Cell Lung

China
The University of Hong Kong

Completed

Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLC

Lung Cancer

Hong Kong
Novartis Pharmaceuticals

Completed

Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Metastatic Renal Cell Carcinoma

United States, Canada, France, Italy, Spain, Belgium, Germany, Hungary, Saudi Arabia, Netherlands, Switzerland, Australia, Austria, Poland, Sweden, United Kingdom, Thailand, Korea, Republic of, Greece, Israel, Argentina, Japan, Colo... and more
Novartis Pharmaceuticals

Completed

A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment

Hepatocellular Carcinoma

Taiwan, Hong Kong, China, Thailand, Korea, Republic of, Singapore, Japan
AstraZeneca

Completed

A Retrospective, Non-interventional, Multicenter, Observational Chart Review Study to Explore the Clinical Benefits of Retreatment With TKI in the Real World. (SEQUENCE)

Locally Advanced or Metastatic EGFR Mutated NSCLC.

Taiwan
Hellenic Oncology Research Group
University Hospital of Crete

Terminated

Combination of Erlotinib and Bevacizumab as Second-line Treatment in Patients With Non-small Cell Lung Cancer

Non-small-cell Lung Cancer

Greece
Ontario Clinical Oncology Group (OCOG)
Novartis Pharmaceuticals

Completed

A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands (DOVE)

Recurrent Adenoid Cystic Carcinoma of the Salivary Glands | Metastatic Adenoid Cystic Carcinoma of the Salivary Glands | Salivary Gland Cancers | ACC

Canada
Ontario Clinical Oncology Group (OCOG)
Novartis Pharmaceuticals

Terminated

A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy (DOVE-M)

Advanced Malignant Pleural Mesothelioma | MPM

Canada
Lady Davis Institute
Jewish General Hospital

Unknown

A Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors (TKI) for EGFR -Mutant Advanced NSCLC (CURCUMIN)

Lung Cancer

Canada
Kyowa Kirin Co., Ltd.

Completed

ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer

Non-small-cell Lung Cancer

Japan
National OncoVenture
Hanmi Pharmaceutical Company Limited

Completed

NOV120101 Phase 2 Study in NSCLC Patients With Aquired Resistance to 1st Generation EGFR Tyrosine Kinase Inhibitors (NSCLC)

Increased Drug Resistance

Korea, Republic of
AstraZeneca
Parexel

Terminated

TAURAS - T790 AURA ScreenFailure SOC Registry Study (TAURAS)

Non Small Cell Lung Cancer

United States, Korea, Republic of
AstraZeneca
Parexel

Withdrawn

T790M Mutation Positive 2nd Line STandard of cAre Registry (T-STAR)

Non Small Cell Lung Cancer

Italy, Russian Federation, Spain, China, Netherlands, United States, Taiwan, France, Germany
Sun Yat-sen University

Unknown

Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc (NSCLC EGFR TKI)

Advanced Stage Non Small Cell Lung Cancer

China
M.D. Anderson Cancer Center

Terminated

Pegasys in Patients With Chronic Myeloid Leukemia (CML)

Leukemia

United States
Regeneron Pharmaceuticals
Sanofi

Withdrawn

A Study of the Safety and Efficacy of Subcutaneously Administered REGN475 in Patients With Osteoarthritis of the Knee

Osteoarthritis
Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI

Non-small Cell Lung Cancer

China
Auckland District Health Board
Novartis; University of Auckland, New Zealand; IGENZ, Ltd., Auckland

Unknown

1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC (DILIGENCE-1)

Clear Cell Renal Cell Carcinoma

New Zealand
Peking University Third Hospital

Unknown

Endostar Combination With Chemotherapy and EGFR-TKI in Lung Cancer Rechallenging Treatment After Acquired Resistance.

Lung Cancer

China
Oscar Goodman, Jr.
Comprehensive Cancer Centers of Nevada

Withdrawn

A Study of Dovitinib With Androgen Deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer Receiving Primary ADT

Prostate Cancer

United States
University of Athens

Completed

Phase IV Study of Tarceva in Patients With Advanced Stage IIIB/ IV Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

Greece
Armando Santoro, MD

Completed

Identification of EGFR-TKIs Sensitivity or Resistance Markers in NSCLC May Help in Optimal Patient Selection

NON-SMALL-CELL LUNG CANCER

Italy
Groupe Français de Pneumo-Cancérologie

Completed

Retrospective Study in Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) (EGFR-RETRO)

NSCLC Non Small Cells Lung Cancer

France
Seoul National University Hospital

Completed

Dovitinib in Adenoid Cystic Carcinoma

Adenoid Cystic Carcinoma

Korea, Republic of
University of Florida

Withdrawn

Explore the Synergy of Combination TKI Therapy

Healthy Volunteers
Wuhan Union Hospital, China

Unknown

Study of EGFR-TKI to Asymptomatic Brain Metastases of NSCLC (EABM)

Asymptomatic Brain Metastases of Non Small Cell Lung Cancer
Tongji University
Sun Yat-sen University; Peking Union Medical College Hospital; RenJi Hospital; Guangdong... and other collaborators

Completed

Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 Mutation (ML20981)

Non-small Cell Lung Cancer

China
Wageningen University and Research
Amsterdam UMC, location VUmc; Fonterra (Europe) Cooperatie U.A.; Carezzo B.V.; Hogeschool...

Completed

Increase Protein Intake in Elderly

Markedly Reduced Food Intake

Netherlands
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University; Second Affiliated Hospital...

Unknown

Efficacy and Safety Study of Bevacizumab Plus Chemotherapy in EGFR-TKI Resistant Non-Squamous Non-Small Cell Lung Cancer

Lung, Carcinoma
Betta Pharmaceuticals Co., Ltd.

Completed

Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose

Non-small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Completed

Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation

Non-small Cell Lung Cancer | Brain Metastases

China
Betta Pharmaceuticals Co., Ltd.

Completed

Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients (ICOGEN)

Non-small Cell Lung Cancer

China

Search clinical trials for: TKI 258

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Chile

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations